Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of this medicinal product is substantial. |
Clinical Added Value
| no clinical added value |
MEZAVANT LP does not provide any improvement in actual benefit (IAB V) compared to the other mesalazine-based proprietary medicinal products that are available on the market for the induction and maintenance treatment of patients suffering from slight to moderate attacks of ulcerative colitis. |
English version
Contact Us
Évaluation des médicaments
